Safety and Feasibility of Anti-CD19 CAR T Cells Expressing Inducible IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-cell Lymphoma
In this study, Lei et al. first report the preclinical and the phase 1 clinical trial results of CD19-specific CAR-T cells capable of expressing interleukin (IL)-7 and chemokine (C-C motif) ligand (CCL)-19 ( 7 × 19 CAR-T cells) in patients with R/R LBCL.